Quick Takeaways:
- IDEXX Laboratories introduced two key advances in vet oncology, adding canine mast cell tumor detection to its Cancer Dx Panel (mid-2026, North America) and rolling out FNA cytology on inVue Dx (Q4’25). Together, they enable earlier detection and faster, in-clinic decision-making, now covering >1/3 of canine cancers.
- Already used by 5,500+ clinics, the Cancer Dx Panel detects lymphoma up to 8 months earlier. The new mast cell test comes at no added cost, delivers results in 2–3 days, and fits existing workflows. Meanwhile, inVue Dx FNA cytology offers real-time, slide-free analysis of skin masses with optional pathologist review.
- With mast cell tumors among the most common dog cancers and often mistaken for benign lumps, early and accurate diagnosis remains a challenge. IDEXX’s expansion bridges this gap and moves closer to making proactive cancer screening and rapid diagnosis standard practice in veterinary care.
Why It Matters?
By expanding Cancer Dx and inVue Dx, IDEXX tightens its grip on veterinary oncology workflows, nudging clinics toward proactive, panel-based cancer screening rather than reactive testing.
Bundling mast cell detection at no extra cost makes it easier for practices to adopt early screening as a routine standard, while real-time in-clinic cytology reduces referrals and wait times, reinforcing IDEXX’s position as an end-to-end oncology diagnostics partner.
Source: Businesswire
